인쇄하기
취소

RNL Bio aims to conduct Phase IIb trials for RNL-JointStem for osteoarthritis in US

Published: 2013-05-06 06:56:00
Updated: 2013-05-06 06:56:00
RNL Bio, a stem cell biotechnology company, said Thursday that it has filed an Investigational New Drug application (IND) with the US Food and Drug Administration to start phase IIb clinical trials with its adipose-derived stem cell product, termed RNL-JointStem, for the treatment of osteoarthritis.

The company plans to initiate its double-blinded, randomized, positive-control Phase II clini...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.